Aerami Therapeutics
Aerami Therapeutics is a privately-held, clinical-stage pharmaceutical company based in Durham, North Carolina that develops novel inhaled therapies for patients with chronic respiratory diseases, sustained by approximately $133 million in venture funding across nine rounds since 2014.
- Company typePrivate
- Founded2010
- HeadquartersDurham, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Aerami Therapeutics does
Aerami Therapeutics is a privately-held, clinical-stage pharmaceutical company headquartered in Durham, North Carolina, founded in 2010. The company focuses on developing novel inhaled therapies for the treatment of chronic diseases, with a particular emphasis on respiratory diseases including diabetes-related respiratory complications and other conditions requiring inhalation-based drug delivery. Aerami's stated differentiation rests on advanced drug-device combination delivery systems designed to enable targeted pulmonary therapeutics.
The company operates with a small team of 11-50 employees and has been sustained through venture capital, raising approximately $133 million across nine funding rounds from 2014 through 2022, with disclosed institutional participation from SternAegis and Molex Ventures (which led rounds in 2018 and 2019). Aerami Therapeutics Holdings, Inc. is the legal entity, which filed a Form D with the US SEC in September 2022 for a $20 million exempt securities offering. The leadership team includes Anne C. Whitaker as Chairman of the Board, Lisa Yañez as incoming Chief Executive Officer, and Barry Deutsch as CFO.
Aerami's business model is preclinical/clinical pharmaceutical development: it has no commercially approved products, no disclosed revenue, and no public pricing. Its sole identified end-segment is patients suffering from respiratory diseases requiring inhalation therapeutics, addressed through what the company describes as advanced drug delivery technology. The company's monetization path is contingent on future regulatory approval and commercialization of its inhaled therapeutic candidates rather than current product sales, licensing, or partnership revenue disclosed in available material.
Aerami Therapeutics firmographics
Firmographics- Name
- Aerami Therapeutics
- Legal name
- Aerami Therapeutics Holdings, Inc.
- Website
- https://aerami.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Aerami Therapeutics is a privately-held, clinical-stage pharmaceutical company based in Durham, North Carolina that develops novel inhaled therapies for patients with chronic respiratory diseases, sustained by approximately $133 million in venture funding across nine rounds since 2014.
- Ownership category
- akta.pro rank
Aerami Therapeutics industry classification
Industry- Product category
- Inhaled Respiratory Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
- akta.pro primary industry
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
- akta.pro secondary industries
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Inhalers (MDI/DPI/SMI) (HLAHAIAI)
Keywords
Where Aerami Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Markets served
Aerami Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Aerami Therapeutics product offering
Product offeringCore offering
Aerami Therapeutics is a clinical-stage biopharmaceutical company developing inhaled drug therapies for chronic and respiratory diseases. The company focuses on novel pulmonary drug delivery systems to treat conditions requiring targeted inhaled administration. It is a private, for-profit entity headquartered in Durham, USA, with 11-50 employees.
Product overview
Aerami Therapeutics is a pharmaceutical company based in Durham that focuses on developing treatments for respiratory diseases. Based on the available source material, no specific named products, modules, or branded offerings were identified.
Differentiator
Problem solved
Functional benefit
Companies that use Aerami Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Aerami Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Aerami Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights3 records
Aerami Therapeutics competitors and assessment
Company assessmentDirect peers
- Vectura Group: UK-based specialty pharmaceutical company focused on inhaled drug delivery for respiratory diseases. Aerami's inhaled respiratory platform is directly comparable in mechanism of delivery and therapeutic focus.
- Pulmatrix: Clinical-stage US biotech developing inhaled therapies for respiratory and infectious diseases using proprietary particle engineering. Comparable to Aerami in stage, respiratory focus, and inhaled delivery technology.
- TFF Pharmaceuticals: Clinical-stage company developing inhaled and intranasal therapeutics using a thin-film formulation platform. Comparable in route of delivery and small-cap clinical-stage profile to Aerami.
Emerging players
- Inhalon Biopharma: Emerging biotech developing an inhaled antibody platform for respiratory infectious diseases. Comparable as a niche inhaled therapeutics company, though with a narrower biologic-only focus than Aerami.
- Civitas Therapeutics: Was a US inhaled therapeutics company (acquired by Acorda in 2014) that developed ARCUS inhaled dry-powder platform. Provides a directly comparable device-plus-drug inhaled respiratory model that ultimately transacted with a larger pharma.
- Aradigm Corporation: Was a US specialty pharma developing inhaled liposomal therapies (acquired by Grifols for AAT deficiency). Closely comparable to Aerami in inhaled respiratory / AAT focus and small-cap development profile.
Broad incumbents
- GSK: Global pharma major with one of the largest respiratory franchises (Advair/Relvar/Trelegy). Represents the dominant incumbent in inhaled respiratory therapeutics against which Aerami's niche technology must compete or partner.
- AstraZeneca: Global pharma major with a major respiratory and inhaled biologics franchise (Symbicort, Fasenra). Comparable as both a potential competitor and a likely acquisition/licensing partner for Aerami's platform.
- Viatris (Mylan Upjohn): Large generic and specialty pharma with a substantial respiratory inhalation product portfolio (Dulera, Yupelri, Perforomist). Comparable as a competing developer of generic and branded inhaled respiratory therapies.
Regional players
- Insmed: US-based specialty pharma focused on inhaled antibiotics and pulmonary delivery (e.g., Arikayce). Comparable in the US market as a small-cap inhaled therapeutics developer that has successfully commercialized a respiratory product.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Aerami Therapeutics social profiles
Digital presenceAerami Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aerami Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Aerami Therapeutics funding detail
Funding detailFunding overview
Funding rounds9 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aerami Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aerami Therapeutics
What does Aerami Therapeutics do?
Aerami Therapeutics is a clinical-stage biopharmaceutical company developing inhaled drug therapies for chronic and respiratory diseases. The company focuses on novel pulmonary drug delivery systems to treat conditions requiring targeted inhaled administration. It is a private, for-profit entity headquartered in Durham, USA, with 11-50 employees.
Is Aerami Therapeutics a public or private company?
Aerami Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Aerami Therapeutics founded?
Aerami Therapeutics was founded in 2010. It employs 11 to 50 people.
Where is Aerami Therapeutics based?
Aerami Therapeutics is headquartered in Durham, United States, in the North America region.
Who are Aerami Therapeutics's main competitors?
Direct peers on record are Vectura Group, Pulmatrix and TFF Pharmaceuticals. Emerging players are Inhalon Biopharma, Civitas Therapeutics and Aradigm Corporation. Broad incumbents are GSK, AstraZeneca and Viatris (Mylan Upjohn). Insmed is listed as a regional player.
Does Aerami Therapeutics have an API?
No public API is recorded for Aerami Therapeutics.
What industry is Aerami Therapeutics in?
Aerami Therapeutics's product category is Inhaled Respiratory Therapeutics. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals, with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 32541.